Health ❯ Cardiovascular Disease ❯ Gene Therapy ❯ Clinical Trials

VERVE-102

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Expected to close in the third quarter of 2025, the deal secures Lilly’s control of VERVE-102, a Fast Track–designated gene-editing therapy in Phase 1b trials.